|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_ocn973396828 |
| 003 |
OCoLC |
| 005 |
20231120112214.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
170222s2017 maua ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d OPELS
|d IDEBK
|d EBLCP
|d N$T
|d YDX
|d OCLCF
|d OCLCQ
|d MEU
|d UPM
|d DKU
|d D6H
|d AU@
|d OCLCQ
|d OCLCO
|d UX1
|d VT2
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 066 |
|
|
|c (S
|
| 015 |
|
|
|a GBB730889
|2 bnb
|
| 019 |
|
|
|a 973506691
|a 973755068
|a 973798715
|a 973907039
|a 974033102
|a 1028922417
|a 1030785129
|a 1032692371
|a 1036686561
|a 1058144972
|a 1235115984
|a 1235846805
|
| 020 |
|
|
|a 9780128123911
|q (electronic bk.)
|
| 020 |
|
|
|a 0128123915
|q (electronic bk.)
|
| 020 |
|
|
|a 9780128123904
|q (print)
|
| 020 |
|
|
|a 0128123907
|
| 035 |
|
|
|a (OCoLC)973396828
|z (OCoLC)973506691
|z (OCoLC)973755068
|z (OCoLC)973798715
|z (OCoLC)973907039
|z (OCoLC)974033102
|z (OCoLC)1028922417
|z (OCoLC)1030785129
|z (OCoLC)1032692371
|z (OCoLC)1036686561
|z (OCoLC)1058144972
|z (OCoLC)1235115984
|z (OCoLC)1235846805
|
| 050 |
|
4 |
|a QH599
|b .C47 2017eb
|
| 072 |
|
7 |
|a SCI
|x 007000
|2 bisacsh
|
| 072 |
|
7 |
|a SCI
|2 ukslc
|
| 082 |
0 |
4 |
|a 572.8/7
|2 23
|
| 245 |
0 |
0 |
|a Chromatin Proteins and Transcription Factors as Therapeutic Targets /
|c edited by Rossen Donev.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press is an imprint of Elsevier,
|c 2017.
|
| 300 |
|
|
|a 1 online resource (xvi, 369 pages :
|b color illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in protein chemistry and structural biology ;
|v volume 107
|
| 546 |
|
|
|a Text in English.
|
| 500 |
|
|
|a Includes indexes.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ScienceDirect, viewed February 24, 2017).
|
| 505 |
8 |
|
|a 2.2.1. Posttranslational Acetylation2.2.2. Oxidation; 2.3. HMGB1-Receptor Families; 2.3.1. Receptor for Advanced Glycation End Products; 2.3.2. Toll-Like Receptors; 2.3.3. Recently Discovered HMGB1 Receptors; 3. HMGB1 in the Nucleus-An Architectural Factor; 3.1. Nucleolar Functions; 3.1.1. DNA Replication, Repair, and V(D)J Recombination; 3.1.2. Gene Transcription Transfer and Delivery; 3.1.3. Nucleosome Structure and Dynamics; 3.1.4. Telomere Homeostasis; 3.2. HMGB1 as a Damage Recognition Protein Mediating the Antitumor Effect of the Chemotherapeutic Drug cis-Platin
|
| 505 |
8 |
|
|a 3.3. HMGB1 Protein-An Important Player in cis-platin-Based Therapy3.3.1. HMGB1 Affects the Repair of DNA Damaged by the Antitumor Drug cis-Platin In Vitro; 3.3.2. The Impact of HMGB1 Protein for the Repair Potential of Human Cancer Cell Lines: A Significant Issue for Therapeut ... ; 4. HMGB1 Outside the Cell; 4.1. HMGB1 as a Signaling Molecule; 4.2. HMGB1 and Diseases; 5. HMGB1 as a Therapeutic Target; 5.1. Antibody-Based Targeting; 5.2. Peptides and Protein Inhibitors of HMGB1; 5.3. Blockage of HMGB1-Receptor Signaling; 5.4. Small Molecules Inhibiting HMGB1
|
| 504 |
|
|
|a Includes bibliographical references and indexes.
|
| 650 |
|
0 |
|a Chromatin.
|
| 650 |
|
0 |
|a Transcription factors.
|
| 650 |
|
6 |
|a Chromatine.
|0 (CaQQLa)201-0062726
|
| 650 |
|
6 |
|a Facteurs de transcription.
|0 (CaQQLa)201-0242208
|
| 650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Biochemistry.
|2 bisacsh
|
| 650 |
|
7 |
|a Chromatin
|2 fast
|0 (OCoLC)fst00859922
|
| 650 |
|
7 |
|a Transcription factors
|2 fast
|0 (OCoLC)fst01154564
|
| 700 |
1 |
|
|a Donev, Rossen,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Chromatin Proteins and Transcription Factors as Therapeutic Targets.
|d Cambridge, MA : Academic Press is an imprint of Elsevier, 2017
|z 0128123907
|z 9780128123904
|w (OCoLC)959869209
|
| 830 |
|
0 |
|a Advances in protein chemistry and structural biology ;
|v v. 107.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/18761623/107
|z Texto completo
|
| 880 |
8 |
|
|6 505-00/(S
|a 7. Effects of the Mesenchymal Cell-State Change on Innate Responses7.1. Dysregulation of Innate Signaling Pathways; 7.2. Epigenetic Silencing of Antiviral Interferons; 8. Therapeutic Targets in the RelA-Triggered Innate/Fibrotic Pathway; 8.1. NFκB/RelA; 8.2. Cyclin-Dependent Kinase 9; 8.3. Bromodomain-Containing Protein 4; 8.4. EZH2 of the PRC2 Repressor Complex; 9. Discussion and Outlook; Acknowledgments; References; Chapter Two: HMGB1 Protein: A Therapeutic Target Inside and Outside the Cell; 1. Introduction; 2. HMGB1-General Overview; 2.1. Structure; 2.2. Posttranslational Modifications
|
| 880 |
8 |
|
|6 505-00/(S
|a 5.5. Oligonucleotide (ODN)-Based HMGB1 Inhibitors6. HMGB1 as a Target of miRs; 6.1. HMGB1 as a Direct Target of miRs; 6.2. HMGB1 as a Regulator of miR Expression; 7. Concluding Remarks; References; Chapter Three: Targeting IKK and NF-κB for Therapy; 1. IKK and NF-κB Signaling; 2. NF-κB Target Gene Specificity; 3. NF-κB in Inflammation, Survival, and Proliferation; 4. IKK and NF-κB Signaling in Disease; 5. Targeting IKK and NF-κB Signaling; 5.1. Receptor Inhibition; 5.2. Adaptor Inhibition as a Potential Strategy; 5.3. IKK Inhibition; 5.4. IκB Stabilization; 5.5. Blocking Nuclear Translocation
|
| 880 |
0 |
|
|6 505-00/(S
|a Front Cover; Chromatin Proteins and Transcription Factors as Therapeutic Targets; Copyright; Contents; Contributors; Preface; Chapter One: Targeting Chromatin Remodeling in Inflammation and Fibrosis; 1. Inflammation Initiation in Mucosal Surfaces; 2. Central Role of NFκB in Regulating the Innate Immune Response; 3. Mechanisms of Inducible Gene Expression; 4. Transcriptional Elongation in Rapid Inflammatory Responses; 5. Mechanisms Linking Chronic Inflammation to Mesenchymal Transition and Airway Fibrosis; 6. The RelA-BRD4 Pathway Links Inflammation, Fibrosis, and Airway Remodeling
|
